1. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study. (1st November 2019) Authors: González-Martín, A; Pothuri, B; Vergote, I; Christensen, RD; Graybill, W; Mirza, MR; McCormick, C; Lorusso, D; Hoskins, P; Freyer, G; Baumann, K; Jardon, K; Redondo, A; Moore, RG; Vulsteke, C; O'Cearbhaill, RE; Lund, B; Backes, F; Barretina-Ginesta, P; Haggerty, AF Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 125 Results of a randomized phase ii trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent chemonaive stromal ovarian tumors. (13th November 2020) Authors: Brown, J; Miller, A; Moxley, K; Backes, F; Nagel, C; Bender, D; Miller, D; Powell, M; Westin, S; Bonebrake, A; Muller, C; Alvarez Secord, A; Crane, E; Schorge, J; Tew, W; Sood, A; Aghajanian, C Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗